Lv6
1976 积分 2024-02-02 加入
Wegovy approved for MASH
5天前
已完结
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
7天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
7天前
已完结
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
7天前
已完结
Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
7天前
已完结
Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells
9天前
已完结
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
9天前
已完结
Clinical Trial Landscape in NASH
9天前
已完结
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
9天前
已完结
Mechanism of action of the bile acid receptor TGR5 in obesity
9天前
已完结
皖公网安备34019202002308
